title: A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients.
abstract: BACKGROUND
  The study of overactive bladder (OAB) symptoms has historically focused on women. However, it is now evident that men, including those with benign prostatic hyperplasia, have OAB symptoms that respond to anticholinergic therapy. The current OAB treatment frequencies by gender are unknown.
  
  
  OBJECTIVE
  The aim of the study was to compare the treatment patterns among men and women diagnosed with OAB.
  
  
  METHODS
  Patients ≥45 yr in the IMS Health data set with more than one diagnosis code for OAB during a 12-mo period ending December 2007.
  
  
  METHODS
  Treated patients filled a prescription for either an anticholinergic or a tricyclic antidepressant medication; untreated patients did not.
  
  
  METHODS
  Frequencies of OAB diagnoses and medical therapies by age and gender were compared.
  
  
  CONCLUSIONS
  Of the 7,244,501 patients ≥45yr with an OAB diagnosis, 24.4% of these were treated; 75.6% went untreated. Only 25.6% of those treated were men. The diagnosis and treatment frequency increased in both men and women as a function of age. However, in every age group, there was a significantly (p<0.001) decreased proportion of men treated compared with women.
  
  
  CONCLUSIONS
  Despite OAB prevalence, many patients receive no medical treatment. Although the usefulness of OAB medications in men is becoming increasingly recognized, men are significantly less likely to be treated with OAB medications than women.
authors.affiliation: Northwestern University, Feinberg School of Medicine, Department of Urology, Chicago, IL 60611, USA.
authors.forename: Brian T
authors.initials: BT
authors.lastname: Helfand
authors.forename: R Mark
authors.initials: RM
authors.lastname: Evans
authors.forename: Kevin T
authors.initials: KT
authors.lastname: McVary
mesh_terms: D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000375:Aging; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D019992:Databases as Topic; D011307:Drug Prescriptions; D004363:Drug Utilization; D005260:Female; D054625:Healthcare Disparities; D006801:Humans; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D015995:Prevalence; D017678:Sex Distribution; D012737:Sex Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000929:Antidepressive Agents, Tricyclic; D018680:Cholinergic Antagonists